

LAW OFFICES
KILYK & BOWERSOX, P.L.L.C.
Intellectual Property Law

RECEIVED
CENTRAL FAX CENTER
FEB 27 2009

From the Desk of
LEONARD D. BOWERSOX

3925 Chain Bridge Road
Suite D-401
FAIRFAX, VA 22030

WARRENTON OFFICE
400 Holiday Court, Suite 102
Warrenton, Virginia 20186

Email: lbowersox@kbpattentlaw.com
Website: <http://www.kbpattentlaw.com>

TEL.: (703) 385-9688
FAC.: (703) 385-9719
(703) 385-9747

PLEASE DIRECT CORRESPONDENCE TO OUR FAIRFAX OFFICE

FACSIMILE TRANSMISSION COVER SHEET

DATE: February 27, 2009 **UNOFFICIAL BUSINESS**

TO: Examiner Jason M. SIMS
U.S. Patent and Trademark Office
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

EXAMINER: Jason M. SIMS, Group Art Unit 1631

RE: U.S. Patent Application No. 10/681,352
For: DIAGNOSTIC METHOD OF SELECTING APPROPRIATE CANCER TREATMENTS
AND SCREENING METHOD OF MEASURING REAGENTS AND CURATIVE
MEDICINES FOR CANCER PATIENTS
Our Ref.: 3190-044

FROM: Nahied K. Usman/Leonard D. Bowersox

FAC. NO.: (571) 273-7540

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 3

Papers Filed Herewith: Unofficial Amendments to the Claims

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (571) 273-7540 on February 27, 2009.

Virginia J. Byers
Printed Name:


Signature

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

RECEIVED
CENTRAL FAX CENTER

FEB 27 2009

UNOFFICIAL COMMUNICATION

U.S. Patent Application No. 10/681,352

Examiner: Jason M. SIMS

Group Art Unit: 1631

Attorney Docket No.: 3190-044

POSSIBLE AMENDMENTS TO THE CLAIMS**Listing of Claims:**

1 - 24 (Canceled)

25. (Previously presented) A method for selecting ~~determining~~ treatments for a cancer patient, comprising:

collecting genomic DNA from the patient;

amplifying the HLA DQB1* (Major histocompatibility complex, class II, DQ beta

1) gene from the genomic DNA using an automated PCR thermal sequencer;

~~determining what~~ identifying the amino acids are encoded by ~~at~~ positions 57 and 67 of the amino acid sequence encoded by the HLA DQB1* (Major histocompatibility complex, class II, DQ beta 1) gene of the patient; and

determining anti-cancer immunotherapy after cancer resection to have a statistically significant probability of prolonging the cancer patient's survival, ~~when by~~ determining that Asp is ~~encoded~~ at position 57 and Val is ~~encoded~~ at position 67 of the amino acid sequence encoded by the HLA DQB1* (Major histocompatibility complex, class II, DQ beta 1) gene; and

selecting anti-cancer immunotherapy after cancer resection, as a treatment for the
patient;

wherein the cancer of the patient ~~comprises~~ is stomach cancer.

26. Canceled.

27. (Withdrawn) A method for determining treatments for a cancer patient, comprising:

determining what amino acids are encoded by positions -9, 19, 26, 85, 89, 90, and 116 of the HLA DQB1 *gene of the patient;

determining what amino acids are encoded by positions 14, 25, 47, and 78, of the DRB1 *gene of the patient;

determining what amino acids are encoded by positions 9, 36, 55, 69, and 76, of the DPB1 *gene of the patient; and

correlating the amino acids encoded at the positions with a cancer treatment having the greatest statically significant probability of prolonging the cancer patient's survival, wherein the cancer treatment comprises immunotherapy, chemotherapy, resection, or a combination thereof.

28. (Withdrawn) The method of claim 27, wherein the cancer patient comprises stomach cancer.